Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

Journal of Clinical Oncology

Volumn 21, Issue 13, 2003, Pages 2564-2573

  Gollob, Jared A ^a   Veenstra, Korina G ^a   Parker, Robert A ^a   Mier, James W ^a   McDermott, David F ^a   Clancy, Daniel ^a   Tutin, Linda ^a   Koon, Henry ^a   Atkins, Michael B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 12; ANTINEOPLASTIC AGENT; INTERLEUKIN 12;

ANEMIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; FEVER; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NAUSEA; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING; ADULT; AGED; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-12; INTERLEUKIN-2; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0038690512     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.119     Document Type: Article

References (26)

1. Trinchieri G: Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridges innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251-276, 1995
2. Brunda MJ, Luistro L, Warrier RR, et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223-1230, 1993
3. Nastala CL, Edington HD, McKinney TG, et al: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153:1697-1706, 1994
4. Cui J, Shin T, Kawano T, et al: Requirement for Va14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623-1626, 1997
5. Coughlin CM, Salhany KE, Gee MS, et al: Tumor cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25-34, 1998
6. Wigginton JM, Gruys E, Geiselhart L, et al: IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 108:51-62, 2001
7. Voest EE, Kenyon BM, O'Reilly MS, et al: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586, 1995
8. Gollob JA, Mier JW, Atkins MB: Clinical use of systemic IL-12 therapy, in Giaccone G, Schilsky R, Sondel P (eds): Cancer Chemotherapy and Biologic Response Modifiers Annual (vol 19). Amsterdam, the Netherlands, Elsevier Science, 2001, pp 353-369
9. Atkins M, Lotze M, Dutcher J, et al: High-dose recombinant interleukin-2 therapy for metastatic melanoma: Analysis of 270 patients treated from 1985-1993. J Clin Oncol 17:2105-2116, 1999
10. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913, 1994
11. Atkins M, Robertson M, Gordon M, et al: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409-417, 1997
12. Gollob JA, Mier JW, Veenstra K, et al: Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6:1678-1692, 2000
13. Wigginton JM, Komschlies KL, Back TC, et al: Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88:38-43, 1996
14. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
15. Gollob JA, Veenstra KG, Mier JW, et al: Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. J Immunother 24:91-98, 2001
16. Smith KA: Rational interleukin-2 therapy. Cancer J Sci Am 3:S137-S140, 1997
17. Cooper MA, Fehniger TA, Turner SC, et al: Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 97:3146-3151, 2001
18. Mehrotra PT, Donnelly RP, Wong S, et al: Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol 160:2637-2644, 1998
19. Parato KG, Kumar A, Badley AD, et al: Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. AIDS 16:1251-1256, 2002
20. Ostensen ME, Thiele DL, Lipsky PE: Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol 138:4185-4191, 1987
21. Robertson MJ, Soiffer RJ, Wolf SF, et al: Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells is differentially regulated by NKSF. J Exp Med 175:779-788, 1992
22. Ross ME, Caligiuri MA: Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 89:910-918, 1997
23. Gollob JA, Schnipper CP, Orsini E, et al: Characterization of a novel subset of CD8+ T cells that expands in patients receiving interleukin-12. J Clin Invest 102:561-575, 1998
24. Rook AH, Wood GS, Yoo EK, et al: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T cell responses. Blood 94:902-908, 1999
25. Ansell SM, Witzig TE, Kurtin PJ, et al: Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99:67-74, 2002
26. Pluda JM, Wyvill K, Little R, et al: A pilot/dose-finding study of interleukin 12 (IL-12) administered to patients with AIDS-associated Kaposi's sarcoma (KS). Proc Am Soc Clin Oncol 18:547a, 1999